MIDEAS

Across TCGA pan-cancer cohorts, MIDEAS Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated MIDEAS data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MIDEAS Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated MIDEAS expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, PRAD, and ESCA are the cancer types where MIDEAS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.925	0.621	.019	20	view →
PRAD	OS	Median	All	0.540	0.990	<.001	12	view →
ESCA	DFS	Median	III,IV	0.080	0.442	<.001	12	view →
LUAD	OS	Median	All	0.239	0.700	<.001	12	view →
STAD	DFS	Median	III,IV	1.000	0.326	.025	8	view →
CESC	DFS	Median	II,III,IV	0.235	0.710	.022	6	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
LUSC	OS	Median	All	0.081	0.818	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SKCM	OS	Median	IV	0.133	0.621	.019	3	view →
COAD	OS	Median	II,III,IV	0.337	0.616	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

MIDEAS–UCEC (DFS)

Open the UCEC breakdown →